StocksRunner logo
mail
search
 
menu
 
Viking Therapeutics
27.55
-1.08%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

VKTX

 

Viking Therapeutics

$27.55

 
-$0.30 | -1.08%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 81.73
 
 
MKT CAP
$ 3.09B
 
52W Low
$ 18.92
 
 
VOL
$ 1.35M
 
P/E Ratio
N/A
 
 
AVG VOL
$ 4.55M
 
RSI
53.91
 
 
TREND
Sideways
 
 
 

Chart

 
 

25.65

29.5

41.16

61.57

 
 
1year
6month
3month
1month
 
VKTX Latest Headlines +
 
 
 
StocksRunner

Explore our VKTX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored VKTX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our VKTX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner
Overview
 
StocksRunner
Trending
 
StocksRunner
Screener
 
StocksRunner
Ideas
 
StocksRunner
Top Rated
 
StocksRunner
Momentum
 
StocksRunner
Earnings
 
 

Recently Viewed

 

VKTX

Viking Therapeutics

 
 
 

Most Trending

 
 
 
Top Banner
 
  Overview  
  
  Analysis  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

VKTX

 

Viking Therapeutics

$27.55

 
-$0.30 | -1.08%
 

 

Chart

 
 

25.65

29.5

41.16

61.57

 
 
1year
6month
3month
1month
 
 
 
 

VKTX Latest Headlines

 
 
 

Why Viking Therapeutics Stock Surged Nearly 20% Higher in April. One of the best catalysts for a stocks rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics (NASDAQ: VKTX) stock in April. Another was a looming late-stage clinical trial of a closely watched pip

 

Tue May 6, 2025

 
Momentum
Potential

Why Viking Therapeutics Stock Was Victorious This Week. Viking Therapeutics (NASDAQ: VKTX) a biotech that has shot to prominence thanks to a weight-loss drug it is developing was a winning stock this week. Over the course of the past five trading days its price rose by almost 18% according to data compiled by S&.P Global Market

 

Fri May 2, 2025

 
Activity
Potential

Notable Friday Option Activity: VKTX FUBO PYPL. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Viking Therapeutics Inc (Symbol: VKTX) where a total volume of 25689 contracts has been traded thus far today a contract volume which is representative of app

 

Fri May 2, 2025

 
Momentum

Where Will Viking Therapeutics Be in 3 Years?. The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug sometimes referred to as a blockbuster can build up a small developer into a mainstream competitor. Thats what investors are hoping for fr

 

Fri May 2, 2025

 
Activity

Why Viking Therapeutics Stock Popped Again Today. Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.

 

Tue Apr 29, 2025

 
Momentum

Viking Therapeutics Q1 Loss Wider Than Expected Sales Nil Stock Dips. VKTXs first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.

 

Thu Apr 24, 2025

 
Earnings
Potential

Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results.

 

Wed Apr 23, 2025

 
Activity
Activity

Viking Therapeutics Stock Dips After Q1 EPS Miss: Details. ) released its first-quarter results after Wednesday'.s closing bell. Here'.s a look at the detailsThe company said the increase in the quarterly net loss was primarily due to the increase in research and development expenses and general and administrative expenses compared to the same period in 2024.Research and development expenses were $41.4 million for the first quarter compared to $24.1 million for ...

 

Wed Apr 23, 2025

 
Momentum

Viking Therapeutics GAAP EPS of -$0.41 misses by $0.06.

 

Wed Apr 23, 2025

 
Earnings

Viking Therapeutics stock slips after wider than expected Q1 loss.

 

Wed Apr 23, 2025

 
Earnings
Momentum

 
 
 
 
 
StocksRunner

Discover VKTX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of VKTX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our VKTX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

VKTX Stock trends

VKTX Stock performance

VKTX Stock analysis

VKTX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 
Post ×
 
0/666
joker